Seres Therapeutics (NASDAQ:MCRB) Earns Neutral Rating from Chardan Capital

Chardan Capital restated their neutral rating on shares of Seres Therapeutics (NASDAQ:MCRB - Free Report) in a research note published on Thursday, MarketBeat reports. The brokerage currently has a $6.00 price objective on the biotechnology company's stock, up from their prior price objective of $1.25.

Other equities research analysts also recently issued reports about the company. StockNews.com downgraded Seres Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 1st. The Goldman Sachs Group reduced their price target on Seres Therapeutics from $20.00 to $15.00 and set a "sell" rating for the company in a research report on Friday, March 14th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $73.67.

Seres Therapeutics Stock Performance

Shares of MCRB traded up $0.10 during mid-day trading on Thursday, hitting $7.05. The company's stock had a trading volume of 129,819 shares, compared to its average volume of 148,168. The stock's 50-day moving average is $11.67 and its two-hundred day moving average is $14.66. The firm has a market capitalization of $61.46 million, a PE ratio of -30.65 and a beta of 2.89. Seres Therapeutics has a one year low of $6.64 and a one year high of $30.60.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biotechnology company reported ($2.24) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($1.57). Analysts expect that Seres Therapeutics will post -0.38 EPS for the current fiscal year.

Institutional Investors Weigh In On Seres Therapeutics

Several large investors have recently modified their holdings of the company. SBI Securities Co. Ltd. increased its position in Seres Therapeutics by 221.8% in the 1st quarter. SBI Securities Co. Ltd. now owns 69,664 shares of the biotechnology company's stock valued at $49,000 after buying an additional 48,013 shares in the last quarter. Vontobel Holding Ltd. raised its stake in shares of Seres Therapeutics by 15.7% during the 1st quarter. Vontobel Holding Ltd. now owns 1,085,966 shares of the biotechnology company's stock worth $760,000 after purchasing an additional 147,671 shares during the period. Millennium Management LLC grew its position in Seres Therapeutics by 77.2% during the fourth quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company's stock valued at $1,505,000 after buying an additional 788,762 shares during the period. Jane Street Group LLC grew its position in Seres Therapeutics by 181.4% during the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock valued at $49,000 after buying an additional 37,866 shares during the period. Finally, Northern Trust Corp increased its holdings in Seres Therapeutics by 20.4% during the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company's stock worth $218,000 after buying an additional 44,461 shares during the last quarter. 59.34% of the stock is currently owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.